Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Regeneron Pharmaceuticals
(NQ:
REGN
)
1,184.69
+5.76 (+0.49%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Regeneron Pharmaceuticals
< Previous
1
2
...
27
28
29
30
31
32
33
34
Next >
WHO Backs Regeneron COVID-19 Antibody Cocktail As It Calls For Equal Access
September 24, 2021
The World Health Organization (WHO) has supported another COVID-19 therapeutic but urged the related companies and governments to address the high price and limited...
Via
Benzinga
Exposures
COVID-19
Ligand Pharmaceuticals Stock Shows Rising Price Performance
September 22, 2021
A Relative Strength Rating upgrade for San Diego-based Ligand Pharmaceuticals stock shows improving technical performance.
Via
Investor's Business Daily
Acceleron Pharma Stock Meets 80-Plus Relative Strength Rating Benchmark
September 22, 2021
Want to build a watch list? Focus on stocks with an 80-plus RS Rating. Acceleron Pharma stock cleared that benchmark with an upgrade to 83.
Via
Investor's Business Daily
Inmune Bio Stock Flashes Robust RS Rating
September 22, 2021
On Wednesday, Inmune Bio stock saw its Relative Strength Rating jump into the 90-plus percentile, to 92 from 85 the day before.
Via
Investor's Business Daily
Where to Invest $100 Right Now
September 22, 2021
These choices may surprise you.
Via
The Motley Fool
3 COVID Stocks to Buy in a Bear Market
September 21, 2021
If COVID-19 shocks the market again, our trio of Fools suggest that you might want to own shares of Moderna, Regeneron, and Figs.
Via
The Motley Fool
Exposures
COVID-19
I-Mab Stock Joins Rank Of Stocks With RS Ratings Over 90
September 20, 2021
Looking for the best stocks to buy? Focus on those with rising relative strength such as I-Mab stock, which saw a (RS) Rating upgrade to 93.
Via
Investor's Business Daily
Sanofi, Regeneron, Share Competitive Libtayo Survival Data in 1L NSCLC
September 20, 2021
Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Sanofi SA (NASDAQ: SNY) hope to expand Libtayo into a broader population with a chemo combo regimen. ...
Via
Benzinga
AbbVie's Pain Is Sanofi's and Regeneron's Gain
September 18, 2021
There are both winners and losers with the new Food and Drug Administration restrictions on JAK inhibitors.
Via
The Motley Fool
Exposures
Product Safety
Look For The Q4 Biotech Bounce In Mid-Small Caps
September 17, 2021
Large-cap biopharma stocks are off their highs because of prospects that drug prices may be directly negotiated through Medicare but several Democrats are not in agreement as to how this could be best...
Via
Talk Markets
Analyst Ratings For Regeneron Pharmaceuticals
September 15, 2021
Regeneron Pharmaceuticals (NASDAQ:REGN) has observed the following analyst ...
Via
Benzinga
Breaking Down The Inflation Numbers Draws Attention To Oil Prices
September 15, 2021
Oil futures (/CL) are up 1% this morning ahead of the crude oil inventories report. While the NY Empire State Manufacturing Index was nearly double forecast. However,...
Via
Benzinga
Exposures
Fossil Fuels
10 Biggest Price Target Changes For Wednesday
September 15, 2021
Morgan Stanley boosted the price target on Adobe Inc. (NASDAQ:
Via
Benzinga
After Regeneron, US Govt. Orders For Additional COVID-19 Therapy From Eli Lilly
September 15, 2021
The U.S. government has announced to purchase additional doses of Eli Lilly And Co's (NYSE: LLY) for its neutralizing antibody therapies for COVID-19. Related...
Via
Benzinga
Exposures
COVID-19
U.S. Govt Calls For Additional Doses Of Regeneron's COVID-19 Antibody Therapy
September 15, 2021
The U.S. government will buy 1.4 million additional doses of Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) COVID-19 antibody cocktail. Read Next: ...
Via
Benzinga
Exposures
COVID-19
The Daily Biotech Pulse: Lilly, Regeneron Ink COVID-19 Drug Deal With US, Regulatory Setback For Calliditas, Theravance To Cut 75% Jobs, 4 IPOs
September 15, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 14) Alcon Inc. (NYSE: ALC)...
Via
Benzinga
Exposures
COVID-19
Tuesday Talk: Up But Under 4500
September 14, 2021
Both the S&P 500 and the Dow closed higher on Monday to end their five day losing streak, while the Nasdaq closed slightly lower than it's Friday close. Closing at 4,469 the S&P 500 was up 10 points...
Via
Talk Markets
Topics
Stocks
Exposures
US Equities
Portfolio Highlights: Quarterly Movers & Shakers, September 2021
September 14, 2021
During the past three months, the S&P 500 index increased 7.3% thanks to the strong economic recovery from the pandemic. All the following high-quality stocks generated strong double-digit gains during...
Via
Talk Markets
Topics
Stocks
Exposures
US Equities
Can Pfizer Beat Sanofi and Regeneron in the Eczema Market?
September 11, 2021
Pfizer's abrocitinib faces some challenges despite encouraging late-stage results for the drug in treating eczema.
Via
The Motley Fool
Analyst Ratings For Regeneron Pharmaceuticals
September 07, 2021
Within the last quarter, Regeneron Pharmaceuticals (NASDAQ:REGN) has observ...
Via
Benzinga
3 Hot Stocks to Buy in September
September 07, 2021
In the stock market, what goes up doesn't have to come down.
Via
The Motley Fool
The Daily Biotech Pulse: Assembly Bio Halts HBV Study, Moderna Initiates Submission For COVID-19 Booster Dose, FDA Nod For BeiGene, Tiziana Out-Licenses Foralumab
September 02, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 1) AbbVie Inc. (NASDAQ: ABBV...
Via
Benzinga
Exposures
COVID-19
Product Safety
Now May Be the Big Moment for These 2 COVID Stocks
September 02, 2021
Their products are seeing a surge in demand.
Via
The Motley Fool
Exposures
COVID-19
5 Stocks That Powered S&P 500 ETF in August
September 01, 2021
The S&P 500 hit a series of record highs in August despite bouts of volatility and uncertainty.
Via
Talk Markets
Topics
Stocks
Exposures
US Equities
The Daily Biotech Pulse: Merck Releases Twin Dose Of Positive Tidings, Astellas Voluntarily Pauses Gene Therapy Study, Ascendis Offering
September 01, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 31) AC Immune SA (NASDAQ: ACIU...
Via
Benzinga
Can COVID-19 Antibody Treatment Help In High-Risk Cases? Mayo Clinic, nference Study Shows Potential
August 30, 2021
Mayo Clinic and nference are jointly conducting artificial intelligence-powered studies evaluating monoclonal antibodies for COVID-19 in patients with an elevated risk...
Via
Benzinga
Exposures
COVID-19
The Daily Biotech Pulse: VectivBio In M&A Mix, Sonnet Biotherapeutics Advances Candidate To Clinics, CEO Transitions At Galapagos, Talis Biomedical
August 31, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 26) Agenus Inc. (NASDAQ: AGEN)...
Via
Benzinga
Pfizer's Abrocitinib Beats Dupixent Late-stage Eczema Trial
August 30, 2021
Pfizer Inc (NYSE: PFE) announced topline data from the JADE DARE Phase 3 trial comparing abrocitinib with Sanofi SA (NASDAQ: SNY) - Regeneron...
Via
Benzinga
Dupixent Becomes First Biologic To Show Benefit In Infant Patients With Atopic Dermatitis
August 30, 2021
A Phase 3 trial evaluating Dupixent (dupilumab) for treating children aged 6 months to 5 years with moderate-to-severe atopic dermatitis met its primary and secondary...
Via
Benzinga
Regeneron Pharmaceuticals Is My Value Stock Of The Week
August 29, 2021
Regeneron Pharmaceuticals, Inc. has become popular over the past year due to its COVID 19 cocktail treatment. It has more than a couple blockbuster drugs, with even more on the way. The best part is...
Via
Talk Markets
< Previous
1
2
...
27
28
29
30
31
32
33
34
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.